Overview

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal impairment relative to matched participants with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Cerevel Therapeutics, LLC